Logo of AdAlta (ASX:1AD)Latest AdAlta (ASX:1AD) News

Page 4
Page 4 of 6

AdAlta Moves Manufacturing of CAR-T Therapy to Australia After Rare Tumour Clearance

AdAlta has secured Australian manufacturing for its lead CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients. This move is a key step toward local clinical trials and boosts the therapy’s global commercial appeal.
Ada Torres
29 Apr 2026

Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.
Logan Eniac
25 Apr 2026

AdAlta and Partners Target Cell Therapy Scale-Up with Automated IRO Platform

AdAlta, Oribiotech, and Cell Therapies have inked a Memorandum of Understanding to deploy Oribiotech’s IRO automated cell therapy manufacturing platform in Australia and Asia Pacific, aiming to slash costs and boost production speed for CAR-T therapies.
Ada Torres
21 Apr 2026

Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.
Logan Eniac
4 Apr 2026

AdAlta’s CAR-T Therapy Delivers Rare Tumour Disappearances in Mesothelioma Trial

AdAlta’s BZDS1901 CAR-T therapy shows remarkable tumour shrinkage and complete responses in advanced mesothelioma patients, doubling expected outcomes and paving the way for higher dosing and expanded trials.
Ada Torres
1 Apr 2026

Healthcare Wrap - Week 13 (23 Mar -> 27 Mar) 2026

Cancer drug data and two separate Mayo Clinic-linked deals drove the biggest moves this week. Investors paid up for clearer routes to hospital rollouts, while one digital screening name fell hard after early gains evaporated.
Logan Eniac
28 Mar 2026

AdAlta Accelerates CAR-T Therapy Development with Shanghai Cell Therapy Group

AdAlta’s subsidiary AdCella has completed its first Joint Development Committee meeting with Shanghai Cell Therapy Group, advancing the development of the CAR-T therapy BZDS1901 with potential timeline acceleration and reduced regulatory risks.
Ada Torres
27 Mar 2026

Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.
Logan Eniac
21 Mar 2026

AdAlta Secures Canadian Patent, Cementing AD-214’s Global Protection

AdAlta Limited has been granted a key Canadian patent for its anti-fibrotic drug AD-214, completing its composition of matter protection across all major commercial markets. This milestone strengthens the company’s intellectual property portfolio and underpins its commercial strategy for AD-214.
Ada Torres
20 Mar 2026

Healthcare Wrap - Week 8 (16 Feb -> 20 Feb) 2026

Two capital raisings and one brutal reset set the tone, even as several companies posted clean growth or strong clinical updates. Radiopharmaceuticals kept delivering good news, but investors still punished supply-chain and cash needs fast.
Logan Eniac
21 Feb 2026

AdAlta Advances CAR-T Collaboration and Boosts Capital Amid $2.44M Half-Year Loss

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.
Ada Torres
20 Feb 2026

Healthcare Wrap - Week 5 (26 Jan -> 30 Jan) 2026

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.
Logan Eniac
31 Jan 2026